Apollomics Inc. Announces $2.0 Million Bridge Financing
Rhea-AI Summary
Apollomics (Nasdaq: APLM) entered a $2.0 million unsecured convertible promissory note with CEO Hung-Wen (Howard) Chen on March 30, 2026 to provide working capital for clinical development and general operations.
The Note bears 0% interest and will automatically convert upon a subsequent equity financing of at least $10.0 million at a 20% discount to that financing's lowest per-share price. The independent Audit Committee and Board approved the related-party terms, with the CEO abstaining from the vote.
Positive
- $2.0M bridge financing secures near-term working capital
- Note carries a 0% interest, avoiding near-term cash interest expense
- Board and independent Audit Committee approved the related-party transaction
Negative
- Related-party financing may raise governance and investor perception concerns
- Automatic conversion at a 20% discount creates potential dilution for existing shareholders
- Note is unsecured, indicating limited creditor protections
News Market Reaction – APLMW
On the day this news was published, APLMW declined 7.89%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 22 | Earnings update | Neutral | +25.7% | First-half 2025 financials with reduced cash and lower R&D expenses. |
| Nov 19 | Litigation settlement | Neutral | -2.6% | Settlement of Cayman litigation with staged cash and legal payments. |
| Nov 17 | Board changes | Neutral | -2.6% | Resignation and replacement of a director plus committee reconstitution. |
| Oct 15 | Listing compliance | Positive | +50.8% | Nasdaq confirmed continued listing, cancelling a planned delisting hearing. |
| Oct 13 | Operational update | Positive | +50.8% | New funding and leadership enabled operational continuity after prior wind-up plans. |
Positive continuity/listing updates previously coincided with strong gains, while other items saw modest moves.
Over the last several months, Apollomics has navigated severe operational stress and subsequent recovery efforts. In August 2025, it disclosed plans to terminate U.S. staff and consider winding up. This was followed by a $4.1M PIPE funding and operational continuity update in October 2025, plus confirmation of continued Nasdaq listing, both accompanied by strong positive price reactions. Later, litigation was settled for US$5.0M, and first-half 2025 results showed sharply reduced cash and lower R&D spend. Today’s bridge financing fits into this ongoing recapitalization narrative.
Market Pulse Summary
The stock moved -7.9% in the session following this news. A negative reaction despite insider-supported bridge funding could fit a market focus on dilution risk and prior balance sheet stress. Historical data show sharp positive responses to major continuity milestones, but this smaller $2.0M bridge at a 20% conversion discount may raise concerns about future equity issuance. The company previously relied on PIPE capital and faced severe cash constraints, so investors may have remained cautious until a larger, longer-term financing solution or operational progress is disclosed.
Key Terms
convertible promissory note financial
equity securities financial
equity financing financial
bridge financing financial
AI-generated analysis. Not financial advice.
FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a
The
The Note is an unsecured obligation of the Company and carries a
The terms of the related-party transaction were reviewed and approved by the Company’s independent Audit Committee and the Board of Directors, with Mr. Chen abstaining from the vote. The transaction followed a comprehensive evaluation of the Company’s financing alternatives and a benchmarking analysis against current market terms for similar bridge financing transactions in the biotechnology sector.
About Apollomics Inc.
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and over 10 other countries. For more information, please visit www.apollomicsinc.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives, including with respect to the anticipated use of proceeds from the Note, the potential conversion of the Note into equity securities, and the Company's future financing plans, are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words.
These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Apollomics cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Apollomics. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including: (i) the impact of any current or new government regulations in the United States and China affecting Apollomics’ operations and the continued listing of Apollomics’ securities; (ii) the inability to achieve successful clinical results or to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomics’ oncology projects; (iii) the failure to commercialize product candidates and achieve market acceptance of such product candidates; (iv) the failure to protect Apollomics’ intellectual property; (v) breaches in data security; (vi) the risk that Apollomics may not be able to develop and maintain effective internal controls; (vii) unfavorable changes to the regulatory environment; and (viii) those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024 (filed with the SEC on April 3, 2025) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, except to the extent required by applicable law.
Investor Contacts: Peter Lin, Chief Financial Officer Apollomics, Inc. 1-650-209-4055 peter.lin@apollomicsinc.com